Clinical Trial Update: 68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating 68Ga-PSMA PET imaging of upper metastatic gastric cancers to determine eligibility for endoradiotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• 68Ga-PSMA-11 (Gallium-68 labeled PSMA-11 radiopharmaceutical)

Snippet

Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Conditions: Upper Digestive Tract Cancer | Phase 2 | Status: RECRUITING